Nav: Home

Researchers identify two potential protein targets for new drug therapies for pancreatic cancer

June 05, 2004

Researchers at Fox Chase Cancer Center in Philadelphia have identified two proteins in pancreatic cancer that may be potential targets for new, more specific drug therapies against this deadly disease. Medical oncologist Steven J. Cohen, M.D., presented the study today at the 40th Annual Meeting of the American Society of Clinical Oncology in New Orleans.

Cohen and his colleagues have identified increased levels of two enzymes, FAP (fibroblast activation protein) and FAK (focal adhesion kinase) in tumor samples and surrounding tissue of pancreatic adenocarcinoma specimens.

Fibroblast activation protein appears on connective tissue, or stromal fibroblasts, supporting the foundation (stroma) of various organs in the intestinal tract. This protein enhances the ability of a tumor to grow. Focal adhesion kinase not only promotes cell growth but also helps tumor cells migrate.

"Our hypothesis was that FAP and FAK would be overexpressed in pancreatic cancer and contribute to poor outcome," Cohen explained.

The researchers analyzed 29 tumor specimens from patients who had curative surgery, comparing them to normal and borderline tumor samples. Pancreatic cancer is characterized by a dense surrounding desmoplasia, or inflammatory reaction, which they hypothesized may contribute to the poor outcome in this disease. The role of FAP and FAK in cell growth and migration made them natural subjects for investigation.

"We found that FAP is overexpressed in over 90 percent of pancreatic adenocarcinomas, with greater expression in the fibroblasts surrounding the tumor than in the distant stroma," Cohen said. "Normal pancreas specimens did not have any FAP expression. "FAK was expressed in all tumor specimens and to a greater degree than in distant stroma. In the stromal tissue, there was a modest correlation between overexpression of FAK and FAP. This suggests that interaction between these proteins may contribute to the ability of pancreatic cancer to metastasize.

"Due to the heterogeneity of the patient samples, we did not see a clear impact of these proteins on clinical outcome such as survival," Cohen explained. "However, the selective overexpression of FAP and FAK compared to normal pancreas in and immediately adjacent to tumor suggests that these proteins are attractive novel therapeutic targets for pancreatic cancer." Cohen added that a number of animal models have been developed to study the effects of FAP on tumor growth.

"FAP promotes tumors in immunodeficient mice, but injecting antisera that blocks the activity of this enzyme inhibits tumor growth. Since targeting FAP appears promising in these preclinical models, we believe our study shows the feasibility of developing such targeted therapy for patients with pancreatic cancer."
-end-
Pancreatic cancer is the fourth leading cause of cancer deaths in American men and the fifth leading cause in American women. An estimated 31,860 new cases of pancreatic cancer will be diagnosed in 2004 and about 31,270 Americans will die of the disease this year, according to the American Cancer Society.

Cohen received a grant from the American Cancer Society to support this research. In addition to Cohen, co-authors of the study at Fox Chase include Neal J. Meropol, M.D., director of the gastrointestinal cancer program; Andre Rogatko, Ph.D., chairman of biostatistics; Louis M. Weiner, M.D., vice president for translational research and chairman of medical oncology; molecular biologist Erica A. Golemis, Ph.D.; medical oncologist Jonathan D. Cheng, M.D. and staff scientist R. Katherine Alpaugh, Ph.D., plus pathologist Irma Palazzo, M.D., of Jeanes Hospital in Philadelphia.

Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa., as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Pancreatic Cancer Articles:

What makes pancreatic cancer so aggressive?
Pancreatic cancer starts forming metastases early. The cancer itself, however, is usually only discovered late.
A one-two punch hits pancreatic cancer where it hurts
Researchers have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumor to make it 'softer' and more responsive to chemotherapy.
New era in precision medicine for pancreatic cancer
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK today.
Sentinels in the blood: A new diagnostic for pancreatic cancer
Tony Hu, a researcher in the Biodesign Virginia G. Piper Center for Personalized Diagnostics and his colleagues have devised a crafty method to identify pancreatic cancer early in its development.
Metastatic pancreatic cancer 'reprogrammed' for malignancy
Metastatic pancreatic cancer -- cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths -- changes its metabolism and is 'reprogrammed' for optimal malignancy, according to new findings reported Jan.
Reason for pancreatic cancer's resistance to chemotherapy found
A pioneering University of Liverpool research team have published a study that identifies the mechanism in the human body that causes resistance of pancreatic cancer cells to chemotherapy.
New discovery paves way for pancreatic cancer treatment
November is Pancreatic Cancer Awareness Month. With the discovery that most pancreatic cancer cases are resistant to chemotherapy, researchers at the University of Notre Dame are looking for better ways to treat patients.
Pancreatic cancer set to become third biggest cancer killer in EU next year
Pancreatic cancer mortality rates are increasing in many countries across the EU and it is estimated that 91,500 deaths will occur from the disease next year, compared with 91,000 from breast cancer.
Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic cells.
Medication against schizophrenia inhibits pancreatic cancer
Scientists from the German Cancer Research Center, Heidelberg, and from McGill University, Montreal, Canada, have discovered that a receptor for the dopamine neurotransmitter promotes growth and spread of pancreatic cancer.

Related Pancreatic Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...